EN DE
Watch Biosino Bio-Technology and Science Incorporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Biosino Bio-Technology and Science Incorporation (8247) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Biosino Bio-Technology and Science Incorporation stock HK$2.48, price HK$2.61, that is 4.8% below the price, quality 31 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Home China · ISIN CNE100000288

BB Biosino Bio-Technology and Science Incorporation logo Thin data Nov 10, 2026

Biosino Bio-Technology and Science Incorporation

8247 · HK

Rising price, but the stock is already about fairly priced and weak company: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Fair value HK$2.48 · Fairly valued 
Revenue last quarter 14% below a year ago. 
Quality 31/100 
Weak Growth (revenue 5y −10.7 %/yr in CNY) 
Loss-making · -24.3% net margin (TTM) 
Negative free cash flow 
Trails peers (3/10) 
Narrow moat 12/100
Thin data 
Estimate
Watch Biosino Bio-Technology and Science Incorporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$6.19 HK$0.5000 Fair Value HK$2.48 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range HK$0.5000 – HK$6.19 · fair‑value band HK$1.86 – HK$3.10 · the HK$2.61 price screens above the HK$2.48 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Biosino Bio-Technology and Science Incorporation in your weekly email

Every Wednesday you see whether Biosino Bio-Technology and Science Incorporation is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagents in Mainland China.

Show moreShow less

The company offers clinical chemistry reagents, including single and double reagents, calibrators, QC products, and washing solution detergents; Elisa kits; rapid tests; and analyzers. It also provides medical and medical inspection services; and produces and sells medical instruments.

Biosino Bio-Technology and Science Incorporation Guangdong has a strategic cooperation agreement with Xiaoshou Medical Technology Co., Ltd. The company was founded in 1988 and is based in Beijing, the People's Republic of China.

Stock analysis

Biosino Bio-Technology and Science Incorporation (8247) currently trades at HK$2.61, while our estimate is HK$2.48, so the stock looks roughly fairly valued today (gap 5.0%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$1.86 (bear) to HK$3.10 (bull), the price of HK$2.61 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Biosino Bio-Technology and Science Incorporation reported revenue of 184M CNY in FY2025 versus 348M CNY in FY2021, a compound −14.7%/yr. Reported net income was −51.1M CNY in FY2025.

Key figures

Market cap HK$377M (≈ $48.0M) Micro · P/S ratio 2.52 · Net margin −27.8% · Return on equity −43.6% · Return on assets (EBIT) −4.8% (5-year average) · Operating margin −16.8% · Revenue (TTM) 171M CNY · Revenue growth (YoY) −14.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 58% below its 52-week high and 161% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at −5%, 8247 screens cheaper than that median.

Fair Value

Bear HK$1.86 Fair Value HK$2.48 Bull HK$3.10
Price HK$2.61 · Downside -4.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 12
How much profit the company makes from its sales and capital
Quality Growth 7
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 26
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 49
How calm the share price moves, does not count
Price momentum 53
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 67
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−29.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.7%
Start year 2020 (pandemic). Over 10 years: −4.4% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.5% (2020) → −32.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 8247, get fair value alerts →

Compare Biosino Bio-Technology and Science Incorporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 150 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −4.8% · Above median
Profitability
Return on assets −12.6% · Bottom 25%
Net margin (12 months) −24.3% · Bottom 25%
Operating margin (12 months) −16.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −14.1% · Bottom 25%
Balance sheet
Debt / equity 0.07× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 2.67× · Pricier than median
P/S (12 months) 1.88× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)27 · sector 12
FUTURE (revenue growth)0 · sector 35
PAST (return on equity)0 · sector 8
HEALTH (low debt)96 · sector 95
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥146.30 ¥164.66 +13% vs 8247
IQVIA Holdings IQV $265.12 $291.63 +10% vs 8247
Illumina, Inc ILMN $207.01 $227.71 +10% vs 8247
Thermo Fisher Scientific Inc TMO $700.22 $686.04 −2% vs 8247
Danaher Corporation DHR $233.02 $209.18 −10% vs 8247
IDEXX Laboratories, Inc IDXX $704.23 $496.48 −30% vs 8247
Lonza Group LONN CHF 666.00 CHF 259.80 −61% vs 8247
Mettler-Toledo International Inc MTD $1,739 $655.06 −62% vs 8247
Agilent Technologies, Inc A $173.96 $64.53 −63% vs 8247
Waters Corporation WAT $460.25 $91.26 −80% vs 8247

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Biosino Bio-Technology and Science Incorporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Biosino Bio-Technology and Science Incorporation Fair Value". https://www.fairvalue-calculator.com/stock/8247

Frequently asked questions

Is Biosino Bio-Technology and Science Incorporation (8247) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$2.48 versus a price of HK$2.61, about 5% lower (fairly valued).
What is the fair value of 8247?
Our estimate for Biosino Bio-Technology and Science Incorporation is HK$2.48 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$2.61.
What is the quality score of 8247?
Biosino Bio-Technology and Science Incorporation has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biosino Bio-Technology and Science Incorporation (8247)?
Our calculated price target is the estimate of HK$2.48 (as of Nov 10, 2026). Cautious scenario HK$1.86, optimistic scenario HK$3.10. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Biosino Bio-Technology and Science Incorporation stock forecast for 2026?
Our estimate puts fair value at HK$2.48, about 5% lower versus a price of HK$2.61 (fairly valued). Cautious scenario HK$1.86, optimistic scenario HK$3.10. The calculation is refreshed regularly with new filings.
What is the revenue of Biosino Bio-Technology and Science Incorporation (8247)?
Biosino Bio-Technology and Science Incorporation reported trailing-twelve-month revenue of about 171M CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Biosino Bio-Technology and Science Incorporation (8247)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biosino Bio-Technology and Science Incorporation it is HK$2.48 per share (as of Nov 10, 2026), against a price of HK$2.61.
Is Biosino Bio-Technology and Science Incorporation stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 8247 trades above its calculated fair value: price HK$2.61, fair value HK$2.48, a gap of about −5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8247?
No. The price is what the market pays today (HK$2.61); the fair value is what the company's own numbers justify (HK$2.48). For Biosino Bio-Technology and Science Incorporation the two are HK$0.1250 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biosino Bio-Technology and Science Incorporation worth?
The market values Biosino Bio-Technology and Science Incorporation at about HK$377M (market capitalisation, as of Nov 10, 2026). Per share that is HK$2.61; our models calculate a fair value of HK$2.48 per share.
What do the bullish and bearish scenarios say about 8247?
Our models span a range for Biosino Bio-Technology and Science Incorporation: cautious scenario HK$1.86, base HK$2.48, optimistic HK$3.10 per share (as of Nov 10, 2026, price HK$2.61). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Biosino Bio-Technology and Science Incorporation (8247)?
Balance-sheet figures for Biosino Bio-Technology and Science Incorporation (as of Nov 10, 2026): return on equity −43.6%, debt of 0.07 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 8247 from its 52-week high?
Biosino Bio-Technology and Science Incorporation trades at HK$2.61, about 58% below its 52-week high of HK$6.19 and 161% above the low of HK$1.00 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.48 is for.
Which stocks are comparable to Biosino Bio-Technology and Science Incorporation?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biosino Bio-Technology and Science Incorporation stock attractive at the current price?
The data as of Nov 10, 2026: price HK$2.61, calculated fair value HK$2.48 (−5%), Quality Score 31/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Biosino Bio-Technology and Science Incorporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biosino Bio-Technology and Science Incorporation (8247)?
The closing price on Nov 13, 2026 was HK$2.61. Our estimate is HK$2.48, about 5% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biosino Bio-Technology and Science Incorporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Biosino Bio-Technology and Science Incorporation

How large is the market capitalisation of Biosino Bio-Technology and Science Incorporation (8247)?
The market capitalisation of Biosino Bio-Technology and Science Incorporation is HK$377M (≈ $48.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biosino Bio-Technology and Science Incorporation (8247)?
The price-to-sales ratio of Biosino Bio-Technology and Science Incorporation is 2.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Biosino Bio-Technology and Science Incorporation (8247)?
The net margin of Biosino Bio-Technology and Science Incorporation is −27.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biosino Bio-Technology and Science Incorporation (8247)?
The return on equity (ROE) of Biosino Bio-Technology and Science Incorporation is −43.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biosino Bio-Technology and Science Incorporation (8247)?
On an EBIT basis the return on assets of Biosino Bio-Technology and Science Incorporation is −4.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biosino Bio-Technology and Science Incorporation (8247)?
The operating margin of Biosino Bio-Technology and Science Incorporation is −16.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biosino Bio-Technology and Science Incorporation (8247)?
Revenue at Biosino Bio-Technology and Science Incorporation is down 14.1% versus a year earlier (3y avg −20.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biosino Bio-Technology and Science Incorporation (8247)?
Earnings per share at Biosino Bio-Technology and Science Incorporation are growing 554% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Biosino Bio-Technology and Science Incorporation (8247) generate?
The free cash flow of Biosino Bio-Technology and Science Incorporation is −32.6M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Biosino Bio-Technology and Science Incorporation (8247) carry?
The net debt of Biosino Bio-Technology and Science Incorporation is 117M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Biosino Bio-Technology and Science Incorporation in the live analysis

One click puts Biosino Bio-Technology and Science Incorporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.